公开(公告)号：US20190134277A1

公开(公告)日：2019-05-09

申请号：US16182307

申请日：2018-11-06

Applicant: Massachusetts Institute of Technology ,  Seattle Children's Hospital d/b/a Seattle Children's Research Institute

Inventor： Omid Veiseh ,  Robert S. Langer ,  Daniel G. Anderson ,  William Shain ,  Brian W. Hanak ,  Samuel R. Browd ,  Robert F. Hevner

IPC: A61L29/08 ,  A61L29/16

Abstract: Neurological implants whose surfaces have been chemically and covalently modified to impart beneficial properties to the neurological implants are described. The neurological implants possess improved biocompatibility compared to a corresponding neurological implant that lacks the chemical modification. Following implantation in a subject, the surface-modified neurological implants induce a lower-foreign body response, compared to a corresponding unmodified product.

公开(公告)号：US20180360765A1

公开(公告)日：2018-12-20

申请号：US16108465

申请日：2018-08-22

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Arturo J. Vegas ,  Joshua C. Doloff ,  Omid Veiseh ,  Minglin Ma ,  Robert S. Langer ,  Daniel G. Anderson

IPC: A61K9/50 ,  C08B37/00 ,  A61K35/39 ,  C12N5/00 ,  A61L29/08 ,  C12N5/071 ,  A61L33/08 ,  A61K9/00 ,  A61L31/10 ,  C08L5/04

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

公开(公告)号：US09867869B2

公开(公告)日：2018-01-16

申请号：US14652011

申请日：2013-12-12

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Daniel G. Anderson ,  Hung-Chieh Chou ,  Michael J. Webber ,  Benjamin C. Tang ,  Yair Levi ,  Yunlong Zhang ,  Rosemary Lynn Kanasty ,  Arturo Jose Vegas ,  Robert S. Langer

IPC: A61K38/28 ,  A61K47/48 ,  G01N33/66 ,  G01N33/74

CPC classification number: A61K38/28 ,  A61K47/54 ,  A61K47/542 ,  A61K47/543 ,  A61K47/549 ,  A61K47/554 ,  G01N33/66 ,  G01N33/74 ,  G01N2333/62

Abstract: Compounds, compositions, and methods for “smart” delivery of a therapeutic, prophylactic or diagnostic agent, such as glucose-mediated delivery of insulin through glucose-sensing insulin derivatives, are provided. The insulin derivatives bind serum albumin or agglomerate in vivo. The insulin derivatives effectively dissociate to release insulin in a hyperglycemic condition, where the complexation of glucose to a glucose-sensing element alters properties of the insulin derivative leading to the dissociation. The compounds, compositions, and methods provide a delivery strategy for both self-regulated and long-term diabetes management.

公开(公告)号：US20140228715A1

公开(公告)日：2014-08-14

申请号：US14116628

申请日：2012-05-14

Applicant: The General Hospital Corporation ,  Massachusetts Institute of Technology

Inventor： Avraham D. Schroeder ,  Carlo Giovanni Traverso ,  Baris E. Polat ,  Kathryn A. Whitehead ,  Daniel G. Anderson ,  Robert S. Langer, Jr. ,  Carl Magnus Schoellhammer ,  Daniel Blankschtein

IPC: A61N7/00

CPC classification number: A61N7/00 ,  A61B5/01 ,  A61B5/073 ,  A61B5/14539 ,  A61B5/14546 ,  A61B5/4839 ,  A61M31/002 ,  A61M37/0092

Abstract: A method of delivering a substance includes providing a substance at a location in a gastrointestinal (GI) tract, excluding a buccal membrane, of a biological body; and applying ultrasonic waves, having a frequency between about 20 kHz and about 10 MHz, at the location. The method can include storing the substance in at least one reservoir and exposing a medium within or of the GI tract to the substance. The method can further include delivering a device into the GI tract, the device including at least one ultrasound transducer and circuitry; powering the at least one ultrasound transducer and circuitry from within the device; and driving the at least one ultrasound transducer, using the circuitry, in a manner causing the at least one ultrasound transducer to emit ultrasonic waves to a medium within or of the GI tract.

Abstract translation: 递送物质的方法包括在生物体的胃肠（GI）道（不包括颊膜）的位置处提供物质; 并且在该位置施加具有约20kHz至约10MHz之间的频率的超声波。 该方法可以包括将物质储存在至少一个储存器中并将GI道内或介质中的介质暴露于物质。 该方法还可以包括将装置递送到胃肠道，该装置包括至少一个超声换能器和电路; 为设备内的至少一个超声换能器和电路供电; 以及使得所述至少一个超声换能器以使得所述至少一个超声换能器向胃肠道内或胃肠道内的介质发射超声波的方式来驱动所述至少一个超声换能器。

公开(公告)号：US20140220346A1

公开(公告)日：2014-08-07

申请号：US14097212

申请日：2013-12-04

Applicant: Memorial Sloan-Kettering Cancer Center ,  Massachusetts Institute of Technology

Inventor： Daniel A. Heller ,  Jasmine Wallas ,  Yair Levi ,  George W. Pratt ,  Daniel G. Anderson ,  Robert Langer

IPC: A61K47/48 ,  A61K49/00

CPC classification number: A61K49/0073 ,  A61K49/0032 ,  A61K49/0052 ,  A61K49/0054 ,  A61K51/065 ,  A61K51/1213 ,  Y10T428/2982

Abstract: In certain embodiments, a nano-sized vehicle (e.g., a nanogel comprising nanoparticles) is provided herein for drug delivery with tunable biodistribution, low toxicity, and degradability, and with demonstrated targeting to bone. The composition is useful, for example, in the treatment of bone disease, particularly bone metastases from cancers such as breast, prostate, or lung cancer.

Abstract translation: 在某些实施方案中，本文提供了纳米级载体（例如，包含纳米颗粒的纳米凝胶）用于具有可调节的生物分布，低毒性和降解性的药物递送，并且已经证实靶向骨。 该组合物可用于例如治疗骨疾病，特别是来自癌症如乳腺癌，前列腺癌或肺癌的骨转移瘤。

公开(公告)号：US20230321230A1

公开(公告)日：2023-10-12

申请号：US18190068

申请日：2023-03-24

Applicant: Massachusetts Institute of Technology

Inventor： Bowen Li ,  Allen Jiang ,  Robert S. Langer ,  Daniel G. Anderson

IPC: A61K39/215 ,  C07K14/47 ,  A61K39/39 ,  C07K14/005

CPC classification number: A61K39/39 ,  A61K39/215 ,  C07K14/005 ,  C07K14/472 ,  A61K2039/53

Abstract: Provided herein are, in various embodiments, methods and compositions comprising polynucleotides (e.g., mRNA) for eliciting an immune response. In certain embodiments, the disclosure provides for methods and compositions for enhancing efficacy of infectious disease treatment (e.g., mRNA vaccines). In still further embodiments, the disclosure provides methods and compositions for enhancing one or more vaccines, such as SARS-CoV-2 mRNA vaccines.

公开(公告)号：US11447796B2

公开(公告)日：2022-09-20

申请号：US17492512

申请日：2021-10-01

Applicant: Massachusetts Institute of Technology

Inventor： Daniel G. Anderson ,  Robert Alexander Wesselhoeft ,  Piotr S. Kowalski

IPC: C12P19/34 ,  C12N15/79 ,  C07H21/04 ,  C12N15/85 ,  C07K16/28 ,  C12N15/11

Abstract: Methods and constructs for engineering circular RNA are disclosed. In some embodiments, the methods and constructs comprise a vector for making circular RNA, the vector comprising the following elements operably connected to each other and arranged in the following sequence: a.) a 5′ homology arm, b.) a 3′ group I intron fragment containing a 3′ splice site dinucleotide, c.) optionally, a 5′ spacer sequence, d.) a protein coding or noncoding region, e.) optionally, a 3′ spacer sequence, f) a 5′ Group I intron fragment containing a 5′ splice site dinucleotide, and g.) a 3′ homology arm, the vector allowing production of a circular RNA that is translatable or biologically active inside eukaryotic cells. Methods for purifying the circular RNA produced by the vector and the use of nucleoside modifications in circular RNA produced by the vector are also disclosed.

公开(公告)号：US11446239B2

公开(公告)日：2022-09-20

申请号：US17024148

申请日：2020-09-17

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Minglin Ma ,  Daniel G. Anderson ,  Robert S. Langer ,  Omid Veiseh ,  Joshua Charles Doloff ,  Delai Chen ,  Christian J. Kastrup ,  Arturo Jose Vegas

IPC: A61K9/00 ,  A61K35/39 ,  A61K9/50 ,  B01J13/04 ,  A61K45/06 ,  A61K35/12 ,  A61K9/48

Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

公开(公告)号：US20220025395A1

公开(公告)日：2022-01-27

申请号：US17492512

申请日：2021-10-01

Applicant: Massachusetts Institute of Technology

Inventor： Daniel G. Anderson ,  Robert Alexander Wesselhoeft ,  Piotr S. Kowalski

IPC: C12N15/85 ,  C07K16/28 ,  C12N15/11

Abstract: Methods and constructs for engineering circular RNA are disclosed. In some embodiments, the methods and constructs comprise a vector for making circular RNA, the vector comprising the following elements operably connected to each other and arranged in the following sequence: a.) a 5′ homology arm, b.) a 3′ group I intron fragment containing a 3′ splice site dinucleotide, c.) optionally, a 5′ spacer sequence, d.) a protein coding or noncoding region, e.) optionally, a 3′ spacer sequence, f) a 5′ Group I intron fragment containing a 5′ splice site dinucleotide, and g.) a 3′ homology arm, the vector allowing production of a circular RNA that is translatable or biologically active inside eukaryotic cells. Methods for purifying the circular RNA produced by the vector and the use of nucleoside modifications in circular RNA produced by the vector are also disclosed.

公开(公告)号：US10851069B2

公开(公告)日：2020-12-01

申请号：US16091330

申请日：2017-04-04

Applicant: Massachusetts Institute of Technology

Inventor： Shady Farah ,  Joshua C. Doloff ,  Robert S. Langer ,  Daniel G. Anderson

IPC: C07D239/49 ,  A61K31/505 ,  A61P29/00 ,  A61K31/404 ,  A61K31/416 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/551 ,  A61K31/553 ,  A61K9/00

Abstract: The present invention provides, in certain embodiments, compositions comprising a uniform population of free, single crystals of a hydrophobic compound. Methods of administering, and processes for preparing, compositions comprising a uniform population of free, single crystals of a hydrophobic compound are also provided.